Peritonectomy for Mesothelioma
Peritonectomy is a surgery that removes peritoneal mesothelioma tumors from the belly. It involves removing all or part of the abdominal lining. It often comes directly before heated chemotherapy (HIPEC). Together, surgery and HIPEC are the gold standard treatment for peritoneal mesothelioma.
Learn More About Peritonectomy in Our Free Mesothelioma Guide
What Is a Mesothelioma Peritonectomy?
Peritonectomy is a surgical treatment for cancers that develop in the abdomen. It removes all or part of the abdominal lining (the peritoneum) and attached tumors. Peritonectomy treats a few cancers, including peritoneal mesothelioma and ovarian cancer. It is a form of cytoreductive surgery (CRS), which means it reduces the amount of tumor tissue in a patient’s body.
For mesothelioma patients, peritonectomy is usually followed by a heated chemotherapy treatment (HIPEC). Together, peritonectomy and HIPEC represent the gold standard in peritoneal mesothelioma treatment.
Research shows most patients go on to receive HIPEC after peritonectomy.
HIPEC stands for heated intraperitoneal chemotherapy. It consists of washing the abdominal cavity with a heated chemo fluid. HIPEC aims to kill cancer cells left behind by peritonectomy or CRS. Heating the chemo liquid and limiting it to the abdomen helps the drugs kill cancer cells more effectively.
CRS with HIPEC may be the most effective treatment for select peritoneal mesothelioma patients. Experts estimate it extends life by several years or more for selected patients.
What to Expect When Undergoing a Mesothelioma Peritonectomy Procedure
Peritonectomy is a common operation that allows surgeons to remove tumors throughout the abdomen. Doctors usually make a large incision to do this surgery, and the recovery process may take months. But patients can take specific steps to prepare for surgery and help ensure a good outcome.
Patients can discuss peritonectomy preparation and recovery with their oncologists. A mesothelioma specialist can help them set realistic expectations.
How to Prepare
Patients can take steps to prepare for their peritonectomy procedures. The care team should provide detailed instructions for required and optional preparations. Patients generally stop eating solid foods about 24 hours before surgery. They also entirely stop eating and drinking starting at midnight the night before surgery.
Before surgery, patients commonly undergo a full workup, sometimes called a pre-admission workup. This can include blood tests, imaging scans and consultations with multiple specialists. This workup helps ensure the patient is prepared and can achieve an optimal outcome.
Because the day may be stressful, patients may want to bring along a comfort bag with helpful supplies like comfy clothes and headphones. They may also need to arrange for transportation to and from the hospital or cancer center.
Each patient’s peritonectomy experience will be unique. Procedure details can differ between surgeons and hospitals, but they generally share a few basic steps.
- The surgeon makes an incision in the abdomen.
- The surgeon uses special tools to remove the affected parts of the abdominal lining.
- The surgeon removes portions of other affected tissues like the stomach or intestines.
- The surgery team preps the patient and administers HIPEC. This step is optional but common.
- The surgeon repairs any important tissues that underwent tumor removal. This step may happen before or after HIPEC.
- The surgeon closes the incision, and the patient moves to the recovery area.
Peritonectomy with HIPEC commonly takes 6 – 14 hours. The treatment team can communicate everything necessary for a patient and their loved ones to navigate this lengthy procedure. Patients should feel free to ask the care team any questions they have about peritonectomy for mesothelioma.
What to Expect After a Mesothelioma Peritonectomy Procedure + HIPEC
Peritonectomy recovery can vary depending on many factors. The treatment team can help patients understand what to expect and how to best manage recovery. In general, patients spend a few weeks in the hospital, then a few months recovering at home.
Recovery From Peritonectomy + HIPEC
Recovery from peritonectomy with HIPEC starts with a couple days of close monitoring. This generally happens in the intensive care unit (ICU), where staff are trained to care for patients after major surgeries. From there, patients usually end up staying in the hospital a total of 10 – 12 days. Once discharged, the care team can work with the patient to ensure effective home care.
Patients may feel tired or less energetic for a few months after surgery. Experts say staying active is helpful and may help prevent complications like blood clots. Patients generally get back to most of their normal daily activities within one month of surgery.
Patients should attend their scheduled follow-up appointments and stay in touch with the treatment team. This can help doctors catch any complications and provide timely treatment.
Benefits of Peritonectomy + HIPEC for Mesothelioma
Peritonectomy can provide several benefits for peritoneal mesothelioma patients, including improved prognosis. Additional peritonectomy benefits include:
- Better survival rates: Patients treated with peritonectomy and HIPEC have better survival rates than those treated with chemo.
- Decreased tumor volume: Peritonectomy removes mesothelioma tumors. This may allow HIPEC to be more effective, as it has less cancer to fight.
- Improved quality of life: Multiple studies show peritonectomy and HIPEC can improve quality of life for patients with abdominal cancers.
Experts estimate peritoneal mesothelioma survival is about one year without peritonectomy and HIPEC. With peritonectomy and HIPEC, patients live about seven years. Patients wondering how this treatment may benefit them should discuss it with their doctors.
Peritonectomy + HIPEC Side Effects and Risks
All medical procedures, including peritonectomy and HIPEC, come with a risk of complications. Peritonectomy side effects may include bleeding, blood clots and other common surgery complications.
Patients can discuss peritonectomy risks and management with their treatment teams. This can help them identify and seek treatment for any side effects that do occur.
- Abscess
- Blood clots
- Digestive issues
- Fistula formation (abnormal connection between two body parts or tissues)
- General fatigue
- Infection
- Severe bleeding
- Tissue perforation (a hole)
- Wounds that will not heal (dehiscence)
Experts say the most common peritonectomy and HIPEC side effects are bleeding and infection. Other side effects occur less frequently. And research indicates this treatment duo has a lower side effect rate than other common surgical procedures.
So patients should watch for side effects as directed by their care teams. But they should also understand the benefits of peritonectomy and HIPEC outweigh the risks for many qualified patients.
Common Questions About Mesothelioma Peritonectomy
What’s the difference between cytoreductive surgery and debulking?
What’s the difference between cytoreductive surgery and peritonectomy?
How much does a peritonectomy procedure cost?
Sources
Al-kasspooles M. Aggressive Treatment for Aggressive Abdominal Cancers: CRS-HIPEC. The University of Kansas Cancer Center. November 2022.
Bao P and Bartlett D. Surgical techniques in visceral resection and peritonectomy procedures. Cancer Journal. May – June 2009;15(3):204-211. doi: 10.1097/PPO.0b013e3181a9c6f0
Baratti D, Kusamura S, et al. Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Cancer. October 2013;49(15):3140-3148. doi: 10.1016/j.ejca.2013.05.027
Foster JM, Sleightholm R, et al. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures. JAMA Network Open. January 2019;2(1):e186847. doi: 10.1001/jamanetworkopen.2018.6847
Mehta SS, Bhatt A, et al. Cytoreductive Surgery and Peritonectomy Procedures. Indian Journal of Surgical Oncology. June 2016;7(2):139-151. doi: 10.1007/s13193-016-0505-5
Schwartz PB, Stahl CC, et al. What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor? Annals of Surgical Oncology. December 2020;27(13):4920-4928. doi: 10.1245/s10434-020-08583-7
Squires III MH, Staley CA, et al. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications. Annals of Surgical Oncology. May 2015;22(5):1739-1745. doi: 10.1245/s10434-014-4025-7
Sugarbaker PH. Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy. Translational Gastrointestinal Cancer. April 2013;2(2):54-74. doi: 10.3978/j.issn.2224-4778.2013.01.02
Sugarbaker PH. Peritonectomy Procedures. Annals of Surgery. January 1995;221(1):29-42. doi: 10.1097/00000658-199501000-00004
Sugarbaker PH and Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. European Journal of Surgical Oncology. July 2017;43(7):1228-1235. doi: 10.1016/j.ejso.2017.01.009
Yan TD, Deraco M, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. May 2011;117(9):1855-1863. doi: 10.1002/cncr.25640
Zaidi MY, Lee RM, et al. Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Annals of Surgical Oncology. January 2020;27(1):156-164. doi: 10.1245/s10434-019-07626-y
Free Mesothelioma Treatment Guide
Katy Moncivais, Ph.D., has more than 15 years of experience as a medical communicator. As the Medical Editor at Mesothelioma.com, she ensures our pages and posts present accurate, helpful information.
Medically
Reviewed by
Francis Perry Wilson, MD
Senior Medical Advisor
Dr. Francis Perry Wilson is the Director of the Clinical and Translational Research Accelerator at the Yale University School of Medicine. He specializes in nephrology and clinical research.
